Skip to main content

Pear Therapeutics, Inc. recently announced the start of a feasibility study for a prescription digital therapeutic (PDT) intended to treat depressive symptoms in people with Multiple Sclerosis (MS). Known as Pear-006, the PDT is intended to be used in combination with disease-modifying treatment. Pear Therapeutics is developing Pear-006 in collaboration with Novartis under the terms of an agreement announced in March 2018.

Read Article